The present disclosure relates generally to the use of methazolamide in therapy. The disclosure particularly relates to regulation of glucose homeostasis and reduction of body mass in patients suffering from or susceptible to diseases and associated conditions, in which undesirably high blood glucose levels are involved or implicated, such as diabetes, syndrome X, hyper-glycaemia, vascular disease and kidney disease. The present disclosure further relates to compounds and agents and compositions thereof for use in the treatment methods.
